GBA1
GBA1 is one of the most important genetic risk factors for Parkinson’s disease. Unlike genes such as PINK1 or PRKN that more often cause clearly inherited early-onset forms, people with certain GBA1 variants have a substantially increased risk of developing Parkinson’s disease, but not everyone with a variant will develop it.
Normal function
GBA1 encodes glucocerebrosidase (GCase), a lysosomal enzyme that helps break down specific lipid molecules. In healthy cells, this is part of normal lysosomal recycling and waste processing. Because lysosomes are essential for clearing damaged proteins and organelles, GBA1 sits directly in the broader autophagy-lysosome pathway.
Mutation and effect
Pathogenic GBA1 variants usually reduce GCase activity or destabilize the protein, which weakens lysosomal function. This can impair the cell’s ability to clear waste and may help the buildup of alpha-synuclein. In Parkinson’s disease, only one mutant copy of the gene is required to increase risk.
Key mechanisms involved
The main mechanisms involve lysosomal dysfunction and impaired protein clearance leading to alpha-synuclein accumulation. Reduced, GCase activity likely makes alpha-synuclein clearance less efficient, while alpha-synuclein buildup may further worsen lysosomal function creating a feedback loop.
Implications for treatment
GBA1-associated Parkinson’s is often considered a distinct clinical subtype. Compared with average idiopathic PD, it is often associated with earlier onset and, in many cohorts, a higher burden of cognitive and non-motor symptoms. The overall disease is still Parkinson’s disease, but the course can be more aggressive in some patients, especially with more severe variants. GBA1 has become a major translational target because it points directly to lysosomal biology. Current standard treatment still follows ordinary Parkinson’s care, but GCase-enhancing strategies, substrate reduction approaches, and GBA1-directed gene therapies are active areas of development. This is one of the clearest examples of a gene shaping a disease-modifying treatment strategy in PD.
Research focus
Research is focused on classifying which variants are most clinically meaningful and the biology behind it, understanding how reduced GCase activity drives neurodegeneration, and testing whether restoring lysosomal function can improve disease course. GBA1 is also central to the broader effort to define PD subtypes based on biology rather than symptoms alone.
Sources
- Sidransky, E., Nalls, M. A., Aasly, J. O., et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease.
- Skrahin, A., Horowitz, M., Istaiti, M., et al. (2024). GBA1-Associated Parkinson’s Disease Is a Distinct Entity.
- Stoker, T. B., Torsney, K. M., & Barker, R. A. (2018). Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinson’s Disease.